Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 23242446)

1.

EGFR mutations in squamous cell lung cancer in never-smokers.

Baik CS, Pritchard CC, Eaton KD, Chow LQ.

J Thorac Oncol. 2013 Jan;8(1):e6-7. doi: 10.1097/JTO.0b013e3182762d49. No abstract available.

PMID:
23242446
2.

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.

Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K.

Br J Cancer. 2006 Nov 20;95(10):1390-5. Epub 2006 Oct 24.

3.

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.

Guo H, Wan Y, Tian G, Liu Q, Kang Y, Li Y, Yao Z, Lin D.

Oncol Rep. 2012 Mar;27(3):880-90. doi: 10.3892/or.2011.1559. Epub 2011 Nov 23.

PMID:
22134479
4.

[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].

Sun LN, Luan HL, Zang FL, Wang M, Dong N, Guo Y, Sun BC, Zhan ZL.

Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):667-70. Chinese.

PMID:
21122380
5.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

PMID:
22982650
6.

A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.

Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M; Okayama Lung Cancer Study Group.

J Thorac Oncol. 2010 Jan;5(1):99-104. doi: 10.1097/JTO.0b013e3181c20063.

PMID:
19898258
7.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

PMID:
21258250
8.

EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.

Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC.

J Thorac Oncol. 2012 Jan;7(1):98-104. doi: 10.1097/JTO.0b013e3182370e30.

PMID:
22124476
9.

Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.

Pennell NA, Yin L, Keshtgarpour M, Ma PC.

J Thorac Oncol. 2012 Jul;7(7):1200-1. doi: 10.1097/JTO.0b013e318250ed89. No abstract available.

PMID:
22706608
10.

Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.

Iyevleva AG, Mitiushkina NV, Karaseva NA, Orlov SV, Volodina LN, Kulikova YE, Lozhkina AM, Ivantsov AO, Tiurin VI, Togo AV, Imyanitov EN.

J Thorac Oncol. 2014 Apr;9(4):e31-3. doi: 10.1097/JTO.0000000000000106. No abstract available.

PMID:
24736087
11.

Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.

Chen YT, Chang JW, Liu HP, Yu TF, Chiu YT, Hsieh JJ, Chen YT, Chen YR, Wu HD, Huang SF.

J Thorac Oncol. 2011 Dec;6(12):2027-35. doi: 10.1097/JTO.0b013e3182307e92.

PMID:
22052229
12.

Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions.

Hung MS, Lin CK, Leu SW, Wu MY, Tsai YH, Yang CT.

Chang Gung Med J. 2006 Jul-Aug;29(4):373-9.

13.

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.

van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S, Nederlof P.

Ann Oncol. 2007 Jan;18(1):99-103. Epub 2006 Oct 23.

14.

RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.

Tsai TH, Su KY, Wu SG, Chang YL, Luo SC, Jan IS, Yu CJ, Yu SL, Shih JY, Yang PC.

Eur Respir J. 2012 Mar;39(3):677-84. doi: 10.1183/09031936.00043511. Epub 2011 Jun 30.

15.

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.

J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa.

PMID:
19057271
16.

Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.

Fiorentino M, Giunchi F, Altimari A, Di Tullio P, Gruppioni E, Martorana G, Pinto C.

Oncologist. 2014 Apr;19(4):430. doi: 10.1634/theoncologist.2013-0346. Epub 2014 Mar 20. No abstract available.

17.

An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients.

Kawada I, Soejima K, Watanabe H, Nakachi I, Yasuda H, Naoki K, Kawamura M, Eguchi K, Kobayashi K, Ishizaka A.

J Thorac Oncol. 2008 Oct;3(10):1096-103. doi: 10.1097/JTO.0b013e318186fadd.

PMID:
18827604
18.

Predictors of the response to gefitinib in refractory non-small cell lung cancer.

Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, Baek SM, Park CS, Park CM, Kim YI, Lim SC, Park KO.

Clin Cancer Res. 2005 Mar 15;11(6):2244-51.

19.

Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung.

Park SH, Ha SY, Lee JI, Lee H, Sim H, Kim YS, Hong J, Park J, Cho EK, Shin DB, Lee JH.

J Korean Med Sci. 2009 Jun;24(3):448-52. doi: 10.3346/jkms.2009.24.3.448. Epub 2009 Jun 12.

20.

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ.

Lung Cancer. 2006 Nov;54(2):201-7. Epub 2006 Sep 7.

PMID:
16956694
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk